Haemonetics Corp HAE Stock Analysis
- NYSE
- Stock
- Market closed · opens Monday 9:30 AM ET
$118.28 down $3.01, 2.48% at close Oct 16
Last close · Previous close $121.29
- Market cap
- At the Oct 16 close
- P/E ratio
- 57.14On last 12 months’ EPS
- Diluted EPS
- $2.07Last 12 months
- Dividend yield
- NoneLast 12 months
Price chart
$118.28down $3.01, 2.48%Fri, Oct 16 session
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$121.29Oct 15
- Volume471.52KOct 16 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume727.92KLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $48.98 to $123.77; now $118.28
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Oct 16 close. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
HAE beat the S&P 500 in 4 of 7 periods.
| Period | HAE and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | HAE: up 11.3% S&P 500: up 1.5% | HAE beat the S&P 500 by 9.8 percentage points Beat |
| 3M | HAE: up 50.7% S&P 500: up 1.9% | HAE beat the S&P 500 by 48.8 percentage points Beat |
| YTD | HAE: up 47.6% S&P 500: up 12.8% | HAE beat the S&P 500 by 34.8 percentage points Beat |
| 1Y | HAE: up 137.7% S&P 500: up 16.8% | HAE beat the S&P 500 by 120.9 percentage points Beat |
| Long term | ||
| 3Y | HAE: up 31.3% S&P 500: up 81.5% +9.5% vs +22.0% a year | HAE trailed the S&P 500 by 50.2 percentage points Trailed |
| 5Y | HAE: up 69.2% S&P 500: up 83.1% +11.1% vs +12.9% a year | HAE trailed the S&P 500 by 13.9 percentage points Trailed |
| 10Y | HAE: up 246.4% S&P 500: up 319.6% +13.2% vs +15.4% a year | HAE trailed the S&P 500 by 73.2 percentage points Trailed |
$10,000 invested in HAE 10 years ago (Oct 14, 2016) would be worth about $34,635 at the close on , with dividends reinvested. The same amount in the S&P 500 would be worth about $41,964.
HAE beat the S&P 500 in 4 of 7 periods.
| Period | HAE and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | HAE: up 11.3% S&P 500: up 1.2% | HAE beat the S&P 500 by 10.1 percentage points Beat |
| 3M | HAE: up 50.7% S&P 500: up 1.7% | HAE beat the S&P 500 by 49.0 percentage points Beat |
| YTD | HAE: up 47.6% S&P 500: up 11.9% | HAE beat the S&P 500 by 35.7 percentage points Beat |
| 1Y | HAE: up 137.7% S&P 500: up 15.5% | HAE beat the S&P 500 by 122.2 percentage points Beat |
| Long term | ||
| 3Y | HAE: up 31.3% S&P 500: up 75.0% +9.5% vs +20.5% a year | HAE trailed the S&P 500 by 43.7 percentage points Trailed |
| 5Y | HAE: up 69.2% S&P 500: up 71.2% +11.1% vs +11.4% a year | HAE trailed the S&P 500 by 2.0 percentage points Trailed |
| 10Y | HAE: up 246.4% S&P 500: up 258.1% +13.2% vs +13.6% a year | HAE trailed the S&P 500 by 11.7 percentage points Trailed |
$10,000 invested in HAE 10 years ago (Oct 14, 2016) would be worth about $34,635 at the close on , not counting dividends. The same amount in the S&P 500 would be worth about $35,813.
All-time high
$139.48
Closing high on . Now 15.2% below that record.
Split-adjusted daily closes since May 10, 1991.
Stock splits
2
Latest: 2-for-1 on . One share bought before the first split is 4 shares today.
Both splits
- 2-for-1
- 2-for-1
Valuation
Financials
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q1 FY27, the quarter ended Jun 27, 2026. “Last 12 months” means the four quarters from Jun 29, 2025 to Jun 27, 2026, and balance-sheet figures are as of Jun 27, 2026.
Revenue and net income
Last 12 months, with the change from the 12 months before
- Revenue
- $1.35Bup 0.4%
- Net income
- $96.29Mdown 41.1%
- Diluted EPS
- $2.07down 36.7%
Data table
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q2 FY25 (Sep 28, 2024) | $345.51M | $33.83M | $0.66 |
| Q3 FY25 (Dec 28, 2024) | $348.54M | $37.49M | $0.74 |
| Q4 FY25 (Mar 29, 2025) | $330.60M | $57.98M | $1.17 |
| Q1 FY26 (Jun 28, 2025) | $321.39M | $34.03M | $0.70 |
| Q2 FY26 (Sep 27, 2025) | $327.32M | $38.68M | $0.81 |
| Q3 FY26 (Dec 27, 2025) | $338.97M | $44.74M | $0.95 |
| Q4 FY26 (Mar 28, 2026) | $346.35M | −$20.15M | −$0.41 |
| Q1 FY27 (Jun 27, 2026) | $339.38M | $33.01M | $0.72 |
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| FY22 (Apr 2, 2022) | $993.20M | $43.38M | $0.84 |
| FY23 (Apr 1, 2023) | $1.17B | $115.40M | $2.24 |
| FY24 (Mar 30, 2024) | $1.31B | $117.56M | $2.29 |
| FY25 (Mar 29, 2025) | $1.36B | $167.68M | $3.31 |
| FY26 (Mar 28, 2026) | $1.33B | $97.31M | $2.05 |
Margins
- Gross 59.0%
- Operating 11.7%
- Net 7.1%
The percentages above the chart cover the last 12 months; the lines show each quarter. What margins tell you
Cash flow
- $246.54MLast 12 months
Cash from operations minus capital spending: the cash left after the business maintains and grows its assets.
FCF = Operating cash flow − Capital spendingFree cash flow - Operating cash flow$328.15MLast 12 months
- Capital spending$81.61MLast 12 months
- 18.2%Last 12 months
Free cash flow as a share of revenue, both over the last 12 months.
Shareholder returns
- $171.22MLast 12 months
Cash spent repurchasing shares, net of shares issued. Buybacks shrink the share count, so each remaining share owns more of the company.
- Dividends paid$0.00Last 12 months
- Total returned$171.22MLast 12 months
69% of free cash flow
Balance sheet
- $223.38MAs of Jun 27, 2026
Cash plus short- and long-term marketable securities on the Jun 27, 2026 balance sheet.
- Total debt$1.17BAs of Jun 27, 2026
- Net debt$950.77MAs of Jun 27, 2026
- 3.08As of Jun 27, 2026
Current assets divided by current liabilities on the Jun 27, 2026 balance sheet. Above 1 means short-term assets cover the bills due within a year.
Current ratio = Current assets ÷ Current liabilitiesCurrent ratio - 1.40As of Jun 27, 2026
Total debt divided by shareholders’ equity on the Jun 27, 2026 balance sheet: a measure of financial leverage.
D/E = Total debt ÷ Shareholders’ equityDebt-to-equity ratio
Financial strength
- 7 of 9Last 12 months
vs the 12 beforeA 0–9 checklist from accounting professor Joseph Piotroski. Each test compares the last 12 months with the 12 months before and scores a point if it passes. 8–9 is strong; 0–2 is weak.
- ✓Net income was positive: passed
- ✓Operating cash flow was positive: passed
- ✗Return on assets improved: not passed
- ✓Operating cash flow exceeded net income: passed
- ✗Long-term debt fell relative to assets: not passed
- ✓Current ratio improved: passed
- ✓Share count didn’t rise: passed
- ✓Gross margin improved: passed
- ✓Asset turnover (revenue ÷ assets) improved: passed
- 11.3%Last 12 months
Over the last 12 months, Haemonetics’s net income was 11.3% of its shareholders’ equity (averaged over the last four quarter-ends). It describes the past year, not an expected return.
ROE = Net income (last 12 months) ÷ Average equityReturn on equity - 4.0%Last 12 months
Over the last 12 months, Haemonetics’s net income was 4.0% of its total assets (averaged over the last four quarter-ends): what the business earned on everything it owns.
ROA = Net income (last 12 months) ÷ Average total assets
About Haemonetics Corp
Haemonetics is a global medical technology company dedicated to improving the quality, effectiveness and efficiency of health care. Our innovative solutions addressing critical medical needs include a suite of hospital technologies designed to advance standards of care and help enhance outcomes for patients; end-to-end plasma collection technologies to optimize operations for plasma centers; and products to enable blood centers to collect in-demand blood components.
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- Headquarters
- Massachusetts, USA
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- NYSE
- Asset type
- Common stock
- Price history since
HAE news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
HAE stock FAQ
What is HAE stock’s price today?
Haemonetics (HAE) traded at $118.28 at the close on , down $3.01 (2.48%) from the previous close of $121.29. Over the past 52 weeks it has traded between $48.98 and $123.77.
If you invested $1,000 in HAE 10 years ago, how much would you have now?
With dividends reinvested, $1,000 invested in HAE on would be worth about $3,464 at the close on , a total return of +246.4%. The same $1,000 would be worth $1,692 if invested five years ago, $2,377 if invested one year ago, $4,834 if invested 20 years ago, and $13,327 if invested 30 years ago. Past performance doesn’t predict future returns.
What is HAE’s P/E ratio?
HAE trades at 57.1 times its diluted earnings over the four quarters to ($2.07 per share), at the close. (How the P/E ratio works.)
How much revenue does Haemonetics make?
Haemonetics reported $1.4 billion of revenue over the four quarters to , up 0.4% from the twelve months before. In its latest quarter (Q1 FY27, ended ) revenue was $339.4 million, up 5.6% from a year earlier.
Is Haemonetics profitable?
Yes. Haemonetics earned $96.3 million of net income over the four quarters to , a net margin of 7.1%, and its operating margin was 11.7% (what margins tell you).
What are HAE’s earnings per share?
HAE’s diluted earnings per share were $2.07 over the four quarters to , compared with $3.27 in the twelve months before. The latest quarter (Q1 FY27) brought $0.72 per share, against $0.70 a year earlier (how EPS works).
Does HAE pay a dividend?
Haemonetics hasn’t paid a dividend in the last twelve months.
What is HAE’s 52-week high and low?
Over the past 52 weeks HAE has traded as low as $48.98 and as high as $123.77. At $118.28 at the close on , it is 4.4% below that high and 141.5% above the low.
What is HAE’s all-time high?
HAE’s highest closing price was $139.48 on , adjusted for stock splits. At $118.28 at the close on , it is 15.2% below that record.
Has HAE stock ever split?
Yes, twice: 2-for-1 on ; 2-for-1 on . One share bought before the first split would be 4 shares today.
How has HAE stock performed?
Including dividends and measured to the close on , HAE has returned +47.6% so far this year and +137.7% over the past year, and +69.2% over five years (+11.1% a year). Over the same periods the S&P 500, measured by SPY, returned +12.8%, +16.8% and +83.1%. Past performance doesn’t predict future returns.
What sector and industry is Haemonetics in?
Haemonetics is in the Healthcare sector and the Medical Instruments & Supplies industry, and is headquartered in Massachusetts, USA.
What exchange does HAE trade on?
Haemonetics trades on the NYSE under the ticker symbol HAE. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.